Axonics stock reports USD 3.7 billion Boston Scientific deal

Published on 09/25/2026 at 17:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Axonics stock changed hands when Boston Scientific acquired the medtech company in late 2024. A September 24, 2026 release cites more than USD 1.2 billion in launch-era revenue.

AXNX, US05465P1012, Illustration mit AI erstellt.

Axonics stock (ISIN US05465P1012) is now defined by Boston Scientific's USD 3.7 billion acquisition of the neuromodulation company in late 2024, according to Business Wire. The September 24, 2026 release brings the former Nasdaq-listed company back into current medtech coverage through co-founder Raymond W. Cohen's appointment as chairman of CAIRDAC.

The acquisition fixed the final terms

AK&M states that Boston Scientific completed the acquisition for USD 3.7 billion, with USD 71 per share as the transaction consideration. The same report says Boston Scientific had entered the definitive agreement in January 2024, connecting the final cash value with a deal announced roughly ten months earlier.

The two figures describe different levels of the same transaction. USD 71 was the per-share consideration, while USD 3.7 billion represented the total deal value, giving investors a precise historical reference for the AXNX listing.

Revenue scale remains historical

Business Wire reports that Axonics generated more than USD 1.2 billion in revenue during the four years from commercial launch. That figure covers a cumulative four-year period and should be read as a historical measure of the business that Boston Scientific acquired, rather than as a new quarterly result.

Axonics developed implantable sacral neuromodulation systems for urinary and bowel dysfunction, while its portfolio also included the Bulkamid urethral bulking agent, according to AK&M. The business therefore entered Boston Scientific through a focused urology and pelvic-health technology portfolio.

AXNX is now a deal reference

The decisive market figure for Axonics is the historical USD 71 per-share consideration, paired with the USD 3.7 billion acquisition value. The September 24, 2026 Business Wire release reinforces that Axonics reached the public market in 2018 before becoming part of Boston Scientific in late 2024.